Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.

Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.

Abstract: The present invention relates to the compounds according to Formula (1), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (1) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.

Abstract: The present invention relates to a hard coating including an MT-TiCN layer and an ?-alumina layer which are formed by using a chemical vapor deposition method. A hard coating for cutting tools, which is a coating formed on a base material of a cutting tool formed of a hard material, the coating comprising: a TiCN layer; and an ?-alumina layer formed on the TiCN layer, wherein: the ?-alumina layer has a main peak (maximal strength peak) of (006) plane located between 20-40 degrees during a psi rocking analysis by an XRD; a residual stress in the ?-Al2O3 layer is ?0.9-0.4 GPa; the TiCN layer is composed of TiCxNyOz (x+y+z?1, x>0, y>0, z?0); a composition ratio of C/(C+N) is greater than or equal to 0.4 and smaller than 0.5; the ratio of TC(220)/TC(422) is smaller than 0.45; and the ratio of TC(220)/TC(311) is less than 0.45.

Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).

Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

Abstract: The present invention relates to a hard coating including an MT-TiCN layer and an ?-alumina layer which are formed by using a chemical vapor deposition method. A hard coating for cutting tools, which is a coating formed on a base material of a cutting tool formed of a hard material, the coating comprising: a TiCN layer; and an ?-alumina layer formed on the TiCN layer, wherein: the ?-alumina layer has a main peak (maximal strength peak) of (006) plane located between 20-40 degrees during a psi rocking analysis by an XRD; a residual stress in the ?-Al2O3 layer is ?0.9-0.4 GPa; the TiCN layer is composed of TiCxNyOz (x+y+z?1, x>0, y>0, z?0); a composition ratio of C/(C+N) is greater than or equal to 0.4 and smaller than 0.5; the ratio of TC(220)/TC(422) is smaller than 0.45; and the ratio of TC(220)/TC(422) is less than 0.45.

Abstract: The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5th generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: Disclosed is an alpha alumina (?-Al2O3) thin film comprising the lower layer formed on the base material made from cemented carbide; and the ?-Al2O3 thin film layer formed on the lower layer, wherein when the ?-Al2O3 thin film layer is divided, from the total thickness (T) thereof, into a D1 layer which is from an interface layer to 0.15T, a D2 layer which is from 0.15T to 0.4T, and a D3 layer which is from 0.4T to 1T, an S1 (D3 layer grain size/D1 layer grain size) is 2-5.5 and an S2 (D2 layer grain size/D1 layer grain size) is 1.5-4.

Abstract: The present invent ion relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

Abstract: Disclosed is an alpha alumina (?-Al2O3) thin film comprising the lower layer formed on the base material made from cemented carbide; and the ?-Al2O3 thin film layer formed on the lower layer, wherein when the ?-Al2O3 thin film layer is divided, from the total thickness (T) thereof, into a D1 layer which is from an interface layer to 0.15T, a D2 layer which is from 0.15T to 0.4T, and a D3 layer which is from 0.4T to 1T, an S1 (D3 layer grain size/D1 layer grain size) is 2-5.5 and an S2 (D2 layer grain size/D1 layer grain size) is 1.5-4.

Abstract: Provided is a hard film for a cutting tool formed on a surface of a base material, the hard film being comprised of a nano multi-layered structure formed by sequentially stacking a thin layer A, a thin layer B, a thin layer C and a thin layer D or being comprised of a structure formed by repeatedly stacking the nano multi-layered structure at least twice, wherein the thin layer A is comprised of TixAl1-xN (0.5?x?0.7); the thin layer B is comprised of Al1-y-zTiyMezN (0.4?y?0.7, 0<z?0.1 where Me is at least one of Si, Cr, and Nb); the thin layer C is comprised of AlaTi1-aN (0.5?a?0.7); and the thin layer D is comprised of AlbCr1-bN (0.5?b?0.7).

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: Provided is a hard film formed on a surface of a base material, the hard film being comprised of a nano multi-layered structure formed by stacking a thin layer A, a thin layer B a thin layer C in order of thin layers A-B-A-C from the base material or being comprised of a structure formed by repeatedly stacking the nano multi-layered structure at least twice, wherein the thin layer A is comprised of Ti1-xAlxN (0.3?x?0.7); the thin layer B is comprised of Al1-yCryN (0.3?y?0.7); and the thin layer C is comprised of MeN (where Me is any one of Nb, V, and Cr).